Why It Matters
Prime Therapeutics, a pharmaceutical and health services organization, registered with Red+Blue Strategies for lobbying on health issues, signed Aug. 13. The filing listed no amount and no specific legislation.
Broader Context
Congress is active on pharmaceutical pricing and pharmacy benefit manager (PBM) regulation. The Bipartisan Health Care Act is in committee in the current Congress, alongside the DRUG Act, which would prohibit PBMs from being compensated based on drug list prices and require flat-fee payment structures instead.
Prime Therapeutics previously lobbied on pharmaceutical and health care reform issues. In a quarter three 2008 filing, the company reported lobbying on generic pharmaceuticals, healthcare reform, and Medicare Part D. In early 2021, Prime Therapeutics lobbied on the Lower Health Care Costs Act and the Consolidated Appropriations Act through Hooper, Lundy & Bookman PC.
Spot something wrong? Report an issue with this article